Acute myeloid leukaemia
CD DiNardo, HP Erba, SD Freeman, AH Wei - The Lancet, 2023 - thelancet.com
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …
past decade has witnessed an increasingly improved scientific understanding of the …
Acute myeloid leukemia: current progress and future directions
H Kantarjian, T Kadia, C DiNardo, N Daver… - Blood cancer …, 2021 - nature.com
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
Recent advances in targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …
for younger patients over the last several decades has improved nearly sixfold with the …
[HTML][HTML] Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission
Background Although induction chemotherapy results in remission in many older patients
with acute myeloid leukemia (AML), relapse is common and overall survival is poor …
with acute myeloid leukemia (AML), relapse is common and overall survival is poor …
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
This study investigated the efficacy and safety of azacitidine maintenance in the
posttransplant setting based on the encouraging phase 1/2 reports for azacitidine …
posttransplant setting based on the encouraging phase 1/2 reports for azacitidine …
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Acute myeloid leukaemia (AML) incidence is age dependent, rising markedly in patients
aged! 60 years. Ageing of the European population may therefore contribute to the reported …
aged! 60 years. Ageing of the European population may therefore contribute to the reported …
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach
HM Kantarjian, TM Kadia, CD DiNardo, MA Welch… - Cancer, 2021 - Wiley Online Library
The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …
rapid translation of the information into clinical practice. After more than 40 years of slow …
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
GJ Roboz, F Ravandi, AH Wei… - Blood, The Journal …, 2022 - ashpublications.org
Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in
remission after intensive chemotherapy is predictive of early relapse and poor survival …
remission after intensive chemotherapy is predictive of early relapse and poor survival …
Treating leukemia in the time of COVID-19
S Paul, CR Rausch, N Jain, T Kadia, F Ravandi… - Acta …, 2021 - karger.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic poses several challenges to
the management of patients with leukemia. The biology of each leukemia and its …
the management of patients with leukemia. The biology of each leukemia and its …